Making traditional Chinese medicine more effective, and life healthier.

Academician and Expert Workstation

The workstation will take the “Development of High-Value-Added Products Based on Wild‑Grown Ganoderma Lucidum Under Forest Canopies” project as its strategic cornerstone, deeply integrate research resources, focus on overcoming the technological bottlenecks that constrain industrial upgrading, and establish an end-to-end innovation system spanning from “forest‑under cultivation” to “high‑value‑added products.”

Liu Xuesong

Foreign Member of the Russian Academy of Engineering, Zhejiang University’s Qiu Shi Distinguished Professor, doctoral supervisor, and Executive Deputy Director of the Zhejiang University Institute of Modern Chinese Medicine.

His areas of expertise and research focus on modern pharmaceutical engineering and intelligent manufacturing in the pharmaceutical sector; the integration of next-generation pharmaceutical information technologies with advanced manufacturing techniques; quality‑control methodologies across the entire pharmaceutical and greater‑health value chain; novel pharmaceutical processes and cutting‑edge equipment technologies; and the development of traditional Chinese medicines and health‑related products based on high‑quality, bioactive natural compounds. He has led or participated in more than 30 national and provincial‑level research projects, been recognized with over ten prestigious talent designations, including the National “Ten Thousand Talents Program” and the National Innovation Talent Promotion Program, and received more than 20 national and provincial awards, such as the China Association for Science and Technology’s Qiu Shi Outstanding Young Researcher Award for Technology Transfer and the Ministry of Education’s First Prize for Technological Invention. He spearheaded the formulation of the world’s first ISO international standards for traditional Chinese medicine production processes and quality control, and has chaired or contributed to numerous industry standards for intelligent pharmaceutical manufacturing. He has published over 120 research papers, more than 50 of which are indexed in SCI/EI databases, and holds over 50 authorized invention patents. His achievements have earned him the China Good Design Gold Award, recognition among the Top Ten Scientific and Technological Advances in Intelligent Manufacturing in China, and the overall championship in the System Integration Solutions category of the inaugural China Intelligent Manufacturing Innovation Competition. Under his leadership, his team has achieved key technological breakthroughs in areas such as the modernization of traditional Chinese medicine and the digital‑intelligent transformation of biopharmaceuticals, fostering deep integration between advanced manufacturing technologies, smart equipment, quality‑control systems, and pharmaceutical information technologies with the broader pharmaceutical industry. Collaborating with leading industry players, he has helped establish several pioneering smart factories, setting benchmarks for the intelligent transformation of traditional pharmaceutical enterprises. To date, he has developed over 200 health‑related products, standardized 39 classic traditional formulas, and established more than 400 standards for formulated granules, thereby driving the intelligent upgrading of the pharmaceutical sector and providing robust support for the Healthy China initiative.

Doctoral Innovation Station

The JibaiChuan Dr. Chen Xiangjun Innovation Station was established under the leadership of Professor Chen Xiangjun, a researcher selected for Zhejiang University’s “Hundred Talents Program” and a doctoral supervisor. It currently comprises four PhDs in the medical field and six company‑based medical experts and other internal staff members.

Chen Xiangjun

Researcher at the School of Medicine, Zhejiang University; doctoral supervisor; recipient of the “Hundred Talents Program”; postdoctoral fellow at the School of Life Sciences, Tsinghua University.

Dedicated to the study of hereditary and age‑related ophthalmic diseases, the research emphasizes the integration of basic and translational sciences, aiming to develop innovative strategies for the precise prevention and treatment of tissue and organ degeneration during aging, along with their clinical applications. In 2019, the team was awarded the Second Prize of the National Science and Technology Progress Award for “Innovative Research and Technological Applications of Key Strategies for the Precise Prevention and Treatment of Cataracts.” To date, more than 40 papers have been published in internationally renowned journals such as Nature, JACS Au, and Journal of Medicinal Chemistry, with 25 of these authored as first or corresponding author. These publications have been reviewed and cited by leading international journals, including The Lancet, Nature, and Science. Currently, the researcher leads several projects funded by the National Natural Science Foundation, the Zhejiang Provincial Outstanding Young Scientists Fund, and the Zhejiang Provincial Key R&D Program.

Patent Certificate